Most Active Biotech Investors in Menlo Park 2026

9 firms writing Biotech checks in Menlo Park, led by Norwest Venture Partners, F-Prime, Venrock Healthcare Capital Partners — ranked by verified deal count.

Biotech in Menlo Park accounts for 4 tracked companies with verified cap-table data, 4 of which disclose round sizes totalling $1.1B. The median disclosed raise is $300M, and the largest is ReCode Therapeutics at $570M, ahead of BillionToOne ($300M) and Apreo Health ($212M).

The names that recur most often on these biotech cap tables are OrbiMed (1 company), Colt Ventures (1 company), InterWest (1 company), MPM Capital (1 company), Pfizer Venture Investments (1 company), Vida Ventures (1 company). By latest disclosed round, the market skews Series B (2), Series D (1), Series A (1).

Best funded Biotech in Menlo Park companies

  1. ReCode Therapeutics — $570M (latest: Series B)
  2. BillionToOne — $300M (latest: Series D)
  3. Apreo Health — $212M (latest: Series B)
  4. Aether Bio — $49M (latest: Series A)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library